Trial Profile
Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Cyclophosphamide; Fludarabine; Mycophenolate mofetil
- Indications Graft-versus-host disease; Transplant rejection
- Focus Therapeutic Use
- 24 Sep 2021 Status changed from active, no longer recruiting to completed.
- 19 Feb 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 19 Feb 2020 Planned primary completion date changed from 1 Mar 2019 to 1 Jul 2021.